Rapport Therapeutics Reports Q2 2025 Financials and Progress

Rapport Therapeutics, Inc. ( (RAPP) ) has released its Q2 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to its investors.

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders. The company recently reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical trials and financial standing.

Rapport Therapeutics announced the full enrollment of its Phase 2a trial for RAP-219 in patients with drug-resistant focal onset seizures, with results expected in September 2025. Additionally, the company has initiated a Phase 2 trial for RAP-219 in bipolar mania, with results anticipated in the first half of 2027. The company ended the quarter with $260.4 million in cash and investments, which is expected to fund operations through 2026.

Key financial metrics include a net loss of $26.7 million for the second quarter, an increase from the previous year, primarily due to higher research and development expenses. The company’s cash position decreased slightly from the previous quarter, reflecting operational expenditures. Despite these losses, the company remains financially stable with a strong cash runway.

Rapport Therapeutics continues to advance its lead program, RAP-219, which targets specific neurological conditions. The company’s precision approach aims to provide differentiated treatments compared to traditional medications, with ongoing trials in focal onset seizures, bipolar mania, and plans for diabetic peripheral neuropathic pain.

Looking ahead, Rapport Therapeutics is focused on executing its clinical milestones and expanding its pipeline. The management remains optimistic about the potential of RAP-219 and its precision neuroscience platform to deliver transformative treatments and drive long-term shareholder value.